Literature DB >> 30070724

Androgen Receptor Enhances Hepatic Telomerase Reverse Transcriptase Gene Transcription After Hepatitis B Virus Integration or Point Mutation in Promoter Region.

Chiao-Ling Li1, Chen-Yu Li1, You-Yu Lin2, Ming-Chih Ho3, Ding-Shinn Chen2,4, Pei-Jer Chen2,4,5, Shiou-Hwei Yeh1,5,6.   

Abstract

The gender disparity of hepatocellular carcinoma (HCC) is most striking in hepatitis B virus (HBV)-related cases. The majority of such HCC cases contain integrated HBV, and some hotspot integrations, such as those in the telomerase reverse transcriptase gene (TERT) promoter, activate gene expression to drive carcinogenesis. As the HBV genome contains both androgen-responsive and estrogen-responsive motifs, we hypothesized that the integrated HBV DNA renders a similar regulation for downstream gene expression and thus contributes to male susceptibility to HCC. To test this hypothesis, the HBV integration sites and the common mutations in the TERT promoter and tumor protein P53 (TP53) coding region were analyzed in 101 HBV-related HCC cases using a capture-next-generation sequencing platform. The results showed that both HBV integration and -124G>A mutation in the TERT promoter region, occurring in a mutually exclusive manner, were more frequent in male than in female patients with HCC (integration: 22/58 male patients with HCC, 6/36 female patients with HCC, P = 0.0285; -124G>A: 17/62 male patients with HCC, 3/39 female patients with HCC, P = 0.0201; in combination, 39/62 male patients with HCC, 9/39 female patients with HCC, P < 0.0001). The effects of sex hormone pathways on the expression of TERT with both genetic changes were investigated using a reporter assay. HBV integration in the TERT promoter rendered the TERT transcription responsive to sex hormones, with enhancement by androgen receptor (AR) but suppression by estrogen receptor, both of which were dependent on hepatocyte nuclear factor 4 alpha. Besides, AR also increased TERT expression by targeting TERT promoter mutations in a GA binding protein transcription factor subunit alpha-dependent manner.
Conclusion: TERT elevation by AR through integrated HBV and point mutation at the TERT promoter region was identified as a mechanism for the male dominance of HBV-related HCCs; telomerase and AR thus may be targets for intervention of HCC.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2019        PMID: 30070724     DOI: 10.1002/hep.30201

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  18 in total

1.  Focal Adhesion Kinase and β-Catenin Cooperate to Induce Hepatocellular Carcinoma.

Authors:  Na Shang; Hao Wang; Thomas Bank; Aldeb Perera; Cara Joyce; Gina Kuffel; Michael J Zilliox; Scott J Cotler; Xianzhong Ding; Asha Dhanarajan; Peter Breslin; Wei Qiu
Journal:  Hepatology       Date:  2019-06-22       Impact factor: 17.425

2.  Specific diacylglycerols generated by hepatic lipogenesis stimulate the oncogenic androgen receptor activity in male hepatocytes.

Authors:  Ya-Wen Cheng; Kai-Wei Chen; Han-Chun Kuo; Ching-Hua Kuo; Wei-Hsiang Lin; Pei-Jer Chen; Shiou-Hwei Yeh
Journal:  Int J Obes (Lond)       Date:  2019-08-27       Impact factor: 5.095

Review 3.  Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification.

Authors:  Saranya Chidambaranathan-Reghupaty; Paul B Fisher; Devanand Sarkar
Journal:  Adv Cancer Res       Date:  2020-11-28       Impact factor: 6.242

Review 4.  Genomics of Viral Hepatitis-Associated Liver Tumors.

Authors:  Camille Péneau; Jessica Zucman-Rossi; Jean-Charles Nault
Journal:  J Clin Med       Date:  2021-04-22       Impact factor: 4.241

5.  Impact of gender as a prognostic factor in HBV-related Hepatocellular Carcinoma: the survival strength of female patients in BCLC stage 0-B.

Authors:  Lihua Yu; Xiaoli Liu; Xinhui Wang; Zhibo Dang; Yuyong Jiang; Xianbo Wang; Zhiyun Yang
Journal:  J Cancer       Date:  2019-07-10       Impact factor: 4.207

6.  Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma.

Authors:  James J Harding; Robin K Kelley; Benjamin Tan; Marinela Capanu; Gian Kinh Do; Jinru Shia; Joanne F Chou; Christine S Ferrer; Chayma Boussayoud; Kerri Muenkel; Hooman Yarmohammadi; Imane El Dika; Danny N Khalil; Carmen Ruiz; Mariam Rodriguez-Lee; Peter Kuhn; John Wilton; Renuka Iyer; Ghassan K Abou-Alfa
Journal:  Oncologist       Date:  2020-07-02

7.  Advances on molecular mechanism of hepatitis B virus-induced hepatocellular carcinoma.

Authors:  Yiming Shao; Lide Su; Rui Hao; Qianqian Wang; Hua Naranmandura
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-02-25

Review 8.  Unique Features of Hepatitis B Virus-Related Hepatocellular Carcinoma in Pathogenesis and Clinical Significance.

Authors:  Sheng-Han Wang; Shiou-Hwei Yeh; Pei-Jer Chen
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

9.  Recurrent HBV Integration Targets as Potential Drivers in Hepatocellular Carcinoma.

Authors:  Selena Y Lin; Adam Zhang; Jessica Lian; Jeremy Wang; Ting-Tsung Chang; Yih-Jyh Lin; Wei Song; Ying-Hsiu Su
Journal:  Cells       Date:  2021-05-23       Impact factor: 6.600

10.  A male-ABCD algorithm for hepatocellular carcinoma risk prediction in HBsAg carriers.

Authors:  Yuting Wang; Minjie Wang; He Li; Kun Chen; Hongmei Zeng; Xinyu Bi; Zheng Zhu; Yuchen Jiao; Yong Wang; Jian Zhu; Hui Zhao; Xiang Liu; Chunyun Dai; Chunsun Fan; Can Zhao; Deyin Guo; Hong Zhao; Jianguo Zhou; Dongmei Wang; Zhiyuan Wu; Xinming Zhao; Wei Cui; Xuehong Zhang; Jianqiang Cai; Wanqing Chen; Chunfeng Qu
Journal:  Chin J Cancer Res       Date:  2021-06-30       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.